Back to Search Start Over

Peptide Vaccination against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients

Authors :
Michael Schmitt
Paul Schnitzler
Stefan Meuer
Lei Wang
Anita Schmitt
Martin Zeier
Angela Hückelhoven-Krauss
Thomas Giese
Claudia Sommerer
Thomas Bruckner
Source :
Vaccines, Volume 9, Issue 2, Vaccines, Vol 9, Iss 133, p 133 (2021)
Publication Year :
2021
Publisher :
MDPI AG, 2021.

Abstract

Introduction: Cytomegalovirus (CMV) reactivation occurs in seronegative patients after solid organ transplantation (SOT) particularly from seropositive donors and can be lethal. Generation of CMV-specific T cells helps to prevent CMV reactivation. Therefore, we initiated a clinical phase I CMVpp65 peptide vaccination trial for seronegative end-stage renal disease patients waiting for kidney transplantation. Methods: The highly immunogenic nonamer peptide NLVPMVATV derived from CMV phosphoprotein 65(CMVpp65) in a water-in-oil emulsion (Montanide™) plus imiquimod (Aldara™) as an adjuvant was administered subcutaneously four times biweekly. Clinical course as well as immunological responses were monitored using IFN-γ ELISpot assays and flow cytometry for CMV-specific CD8+ T cells. Results: Peptide vaccination was well tolerated, and no drug-related serious adverse events were detected except for Grade I–II local skin reactions. Five of the 10 patients (50%) mounted any immune response (responders) and 40% of the patients presented CMV-specific CD8+ T cell responses elicited by these prophylactic vaccinations. No responders experienced CMV reactivation in the 18 months post-transplantation, while all non-responders reactivated. Conclusion: CMVpp65 peptide vaccination was safe, well tolerated, and clinically encouraging in seronegative end-stage renal disease patients waiting for kidney transplantation. Further studies with larger patient cohorts are planned.

Details

ISSN :
2076393X
Volume :
9
Database :
OpenAIRE
Journal :
Vaccines
Accession number :
edsair.doi.dedup.....7b09d220ca5f5fefc096caad55665826
Full Text :
https://doi.org/10.3390/vaccines9020133